Literature DB >> 21685340

How reliable are tests for trachoma?--a latent class approach.

Craig W See1, Wondu Alemayehu, Muluken Melese, Zhaoxia Zhou, Travis C Porco, Stephen Shiboski, Bruce D Gaynor, John Eng, Jeremy D Keenan, Thomas M Lietman.   

Abstract

PURPOSE: Tests for ocular Chlamydia trachomatis have not been well characterized, because there is no gold standard test. Latent class analysis (LCA) was performed to estimate the sensitivity and specificity of laboratory and clinical tests for trachoma in the absence of a gold standard.
METHODS: Individual data from pretreatment, hyperendemic areas in Ethiopia were used. A clustered LCA was performed for three diagnostic tests: PCR and WHO simplified criteria grades of follicular trachoma (TF) and intense trachomatous inflammation (TI).
RESULTS: Data from 2111 subjects in 40 villages were available. TF was estimated to be 87.3% (95% CI, 83.3-90.1) sensitive and 36.6% (95% CI, 23.6-40.3) specific; TI was estimated to be 53.6% (95% CI, 46.1-88.0) sensitive and 88.3% (95% CI, 83.3-92.0) specific, and PCR was estimated to be 87.5% (95% CI, 79.9-97.2) sensitive and 100% (95% CI 69.3-100) specific.
CONCLUSIONS: LCA allows for an estimate of test characteristics without prior assumption of their performance. TF and TI were found to act in a complementary manner: TF is a sensitive test and TI is a specific test. PCR is highly specific but lacks sensitivity. The performance of these tests may be due to the time course of ocular chlamydial infection, and for this reason, results may differ in areas of low prevalence or recent mass treatment (ClinicalTrials.gov number, NCT00221364).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21685340      PMCID: PMC3176003          DOI: 10.1167/iovs.11-7419

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  35 in total

Review 1.  Latent class analysis in medical research.

Authors:  A K Formann; T Kohlmann
Journal:  Stat Methods Med Res       Date:  1996-06       Impact factor: 3.021

2.  Random effects models in latent class analysis for evaluating accuracy of diagnostic tests.

Authors:  Y Qu; M Tan; M H Kutner
Journal:  Biometrics       Date:  1996-09       Impact factor: 2.571

3.  A simple system for the assessment of trachoma and its complications.

Authors:  B Thylefors; C R Dawson; B R Jones; S K West; H R Taylor
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

4.  Severe disease in children with trachoma is associated with persistent Chlamydia trachomatis infection.

Authors:  L D Bobo; N Novak; B Muñoz; Y H Hsieh; T C Quinn; S West
Journal:  J Infect Dis       Date:  1997-12       Impact factor: 5.226

5.  Randomised controlled trial of single-dose azithromycin in treatment of trachoma.

Authors:  R L Bailey; P Arullendran; H C Whittle; D C Mabey
Journal:  Lancet       Date:  1993-08-21       Impact factor: 79.321

6.  An evaluation of the polymerase chain reaction amplicor Chlamydia trachomatis in male urine and female urogenital specimens.

Authors:  A Bianchi; C Scieux; N Brunat; D Vexiau; M Kermanach; P Pezin; M Janier; P Morel; P H Lagrange
Journal:  Sex Transm Dis       Date:  1994 Jul-Aug       Impact factor: 2.830

7.  Detection of Chlamydia trachomatis ocular infection in trachoma-endemic communities by rRNA amplification.

Authors:  Jon L Yang; Kevin C Hong; Julius Schachter; Jeanne Moncada; Takele Lekew; Jenafir I House; Zhaoxia Zhou; Melissa D Neuwelt; Tina Rutar; Colleen Halfpenny; Neelima Shah; John P Whitcher; Thomas M Lietman
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-08       Impact factor: 4.799

8.  An animal model of trachoma II. The importance of repeated reinfection.

Authors:  H R Taylor; S L Johnson; R A Prendergast; J Schachter; C R Dawson; A M Silverstein
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-10       Impact factor: 4.799

9.  Does clinical diagnosis indicate ocular chlamydial infection in areas with a low prevalence of trachoma?

Authors:  Jocelyn Thein; Puning Zhao; Hansheng Liu; Jingjing Xu; Hem Jha; Yinghui Miao; Louis Pizzarello; Lisa Tapert; Julius Schachter; Michèle Mabon; Susan Osaki-Holm; Thomas Lietman; Anne Paxton
Journal:  Ophthalmic Epidemiol       Date:  2002-10       Impact factor: 1.648

10.  Polymerase chain reaction for the detection of ocular chlamydial infection in trachoma-endemic communities.

Authors:  R L Bailey; T J Hampton; L J Hayes; M E Ward; H C Whittle; D C Mabey
Journal:  J Infect Dis       Date:  1994-09       Impact factor: 5.226

View more
  30 in total

1.  American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort.

Authors:  S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

2.  Comparison of the Abbott m2000 RealTime CT assay and the Cepheid GeneXpert CT/NG assay to the Roche Amplicor CT assay for detection of Chlamydia trachomatis in ocular samples from Tanzania.

Authors:  Laura Dize; Sheila West; James A Williams; Barbara Van Der Pol; Thomas C Quinn; Charlotte A Gaydos
Journal:  J Clin Microbiol       Date:  2013-03-13       Impact factor: 5.948

3.  Importance of including borderline cases in trachoma grader certification.

Authors:  Bruce D Gaynor; Abdou Amza; Sintayehu Gebresailassie; Boubacar Kadri; Baido Nassirou; Nicole E Stoller; Sun N Yu; Puja A Cuddapah; Jeremy D Keenan; Thomas M Lietman
Journal:  Am J Trop Med Hyg       Date:  2014-07-07       Impact factor: 2.345

4.  Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions.

Authors:  Jeremy D Keenan; Craig W See; Jeanne Moncada; Berhan Ayele; Teshome Gebre; Nicole E Stoller; Charles E McCulloch; Travis C Porco; Bruce D Gaynor; Paul M Emerson; Julius Schachter; Thomas M Lietman
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-25       Impact factor: 4.799

5.  Pooling ocular swab specimens from Tanzania for testing by Roche Amplicor and Aptima Combo 2 assays for the detection of Chlamydia trachomatis: accuracy and cost-savings.

Authors:  Laura Dize; Sheila West; Thomas C Quinn; Charlotte A Gaydos
Journal:  Diagn Microbiol Infect Dis       Date:  2013-09-27       Impact factor: 2.803

6.  Evaluation of pooled ocular and vaginal swabs by the Cepheid GeneXpert CT/NG assay for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae compared to the GenProbe Aptima Combo 2 Assay.

Authors:  L Dize; S K West; H Mkocha; T C Quinn; C A Gaydos
Journal:  Diagn Microbiol Infect Dis       Date:  2014-11-27       Impact factor: 2.803

Review 7.  Trachoma: an update on prevention, diagnosis, and treatment.

Authors:  Satasuk Joy Bhosai; Robin L Bailey; Bruce D Gaynor; Thomas M Lietman
Journal:  Curr Opin Ophthalmol       Date:  2012-07       Impact factor: 3.761

8.  Comparison of two methods for composite score generation in dry eye syndrome.

Authors:  Craig See; Richard A Bilonick; William Feuer; Anat Galor
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-19       Impact factor: 4.799

9.  Using a nonparametric multilevel latent Markov model to evaluate diagnostics for trachoma.

Authors:  Artemis Koukounari; Irini Moustaki; Nicholas C Grassly; Isobel M Blake; María-Gloria Basáñez; Manoj Gambhir; David C W Mabey; Robin L Bailey; Matthew J Burton; Anthony W Solomon; Christl A Donnelly
Journal:  Am J Epidemiol       Date:  2013-04-01       Impact factor: 4.897

10.  CT694 and pgp3 as serological tools for monitoring trachoma programs.

Authors:  E Brook Goodhew; Jeffrey W Priest; Delynn M Moss; Guangming Zhong; Beatriz Munoz; Harran Mkocha; Diana L Martin; Sheila K West; Charlotte Gaydos; Patrick J Lammie
Journal:  PLoS Negl Trop Dis       Date:  2012-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.